RhoA, a Possible Target for Treatment of Airway Hyperresponsiveness in Bronchial Asthma

DOI Web Site 被引用文献3件 参考文献141件
  • Chiba Yoshihiko
    Department of Pharmacology, School of Pharmacy, Hoshi University, Japan
  • Matsusue Kimihiko
    Faculty of Pharmaceutical Science, Fukuoka University, Japan
  • Misawa Miwa
    Department of Pharmacology, School of Pharmacy, Hoshi University, Japan

この論文をさがす

抄録

Airway hyperresponsiveness to nonspecific stimuli is one of the characteristic features of allergic bronchial asthma. An elevated contractility of bronchial smooth muscle has been considered as one of the causes of the airway hyperresponsiveness. The contraction of smooth muscles including airway smooth muscles is mediated by both Ca2+-dependent and Ca2+-independent pathways. The latter Ca2+-independent pathway, termed Ca2+ sensitization, is mainly regulated by a monomeric GTP-binding protein, RhoA, and its downstream target Rho-kinase. In animal models of allergic bronchial asthma, an augmented agonist-induced, RhoA-mediated contraction of bronchial smooth muscle has been suggested. The RhoA/Rho-kinase signaling is now proposed as a novel target for the treatment of airway hyperresponsiveness in asthma. Herein, we will discuss the mechanism of development of bronchial smooth muscle hyperresponsiveness, one of the causes of the airway hyperresponsiveness, based on the recent studies using animal models of allergic bronchial asthma and/or cultured airway smooth muscle cells. The possibility of RhoA as a therapeutic target in asthma, especially airway hyperresponsiveness, will also be described.

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (141)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ